---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000027"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:10:47.721191+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Travere stockholders approve 2.7M share increase to 2018 equity incentive plan

## Summary
- Stockholders approved amendment increasing authorized shares under 2018 Equity Incentive Plan by 2,700,000 shares.
- Ten directors elected; John Orwin received 50.65M for vs 10.99M withheld.
- Advisory vote on named executive officer compensation passed with 56.25M for, 5.36M against.
- Ernst & Young ratified as independent auditor for FY2023 with 63.81M for, 30K against.
- Plan document filed as Exhibit 99.1.

## SEC filing metadata
- accession: 0001438533-23-000027
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/tvtx-20230517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000027
- JSON: https://secwatch.observer/filing/0001438533-23-000027.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000027.txt

## Key facts
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-17
  source text: Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Election of ten directors at the 2023-05-17 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-17
  source text: Proposal 1: Election of Directors The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2023 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Approval of the Company's 2018 Equity Incentive Plan, as amended at the 2023-05-17 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-17
  source text: Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-05-17 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-17
  source text: Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.